ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Louisville, KY, USA:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Louisville, Kentucky, United States and 145 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Louisville, Kentucky, United States and 211 other locations

low-dose dexamethasone (SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior anti-multiple...

Active, not recruiting
Multiple Myeloma
Drug: Selinexor
Drug: Dexamethasone

Phase 3

Karyopharm Therapeutics
Karyopharm Therapeutics

Louisville, Kentucky, United States and 156 other locations

Locations recently updated

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...

Enrolling
Multiple Myeloma
Biological: BMS-986393

Phase 2

Juno Therapeutics

Saint Matthews, Kentucky, United States and 41 other locations

(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

Phase 2

Celgene
Celgene

Louisville, Kentucky, United States and 48 other locations

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM r...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Eftozanermin alfa

Phase 1

AbbVie
AbbVie

Louisville, Kentucky, United States and 18 other locations

provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...

Active, not recruiting
Multiple Myeloma
Drug: Elranatamab (PF-06863135)

Phase 2

Pfizer
Pfizer

Louisville, Kentucky, United States and 77 other locations

drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemothera...

Enrolling
Multiple Myeloma
Drug: Linvoseltamab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Louisville, Kentucky, United States and 10 other locations

Locations recently updated

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Celgene
Celgene

Louisville, Kentucky, United States and 257 other locations

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

Phase 3

AbbVie
AbbVie

Louisville, Kentucky, United States and 180 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems